Loading...
•
Sep 30, 2022
Eli Lilly Q3 2022 Earnings Report
Eli Lilly reported solid financial results driven by volume growth of key products and the successful launch of Mounjaro.
Key Takeaways
Eli Lilly's Q3 2022 revenue increased by 2%, driven by a 14% increase in volume, with key growth products representing 70% of revenue. The company saw a strong launch for Mounjaro, with $97.3 million in U.S. revenue. EPS increased by 32% to $1.61 on a reported basis and by 12% to $1.98 on a non-GAAP basis.
Revenue increased by 2%, or 7% on a constant currency basis, driven by volume growth of key products.
Mounjaro launch led to $97.3 million in U.S. revenue and $86.0 million related to a sales collaboration agreement for Japan.
Key growth products grew 19% and represented 70% of revenue, excluding COVID-19 antibodies.
EPS increased 32% to $1.61 on a reported basis and increased 12% to $1.98 on a non-GAAP basis.
Eli Lilly
Eli Lilly
Eli Lilly Revenue by Segment
Eli Lilly Revenue by Geographic Location
Revenue by Segment
Mounjaro Revenue
CapyFin.comVerzenio Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comOutside U.S. Revenue
CapyFin.com Forward Guidance
The company has updated certain elements of its 2022 financial guidance on both a reported and non-GAAP basis. The company now anticipates 2022 revenue to be between $28.5 billion and $29.0 billion.
Revenue & Expenses
Visualization of income flow from segment revenue to net income